Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 18, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production
View HTML
Toggle Summary Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 17, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
- Conference Call and Webcast Today, February 2, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Feb. 2, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2021 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 24, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the exclusive license agreement between Arrowhead and GlaxoSmithKline (LSE/NYSE: GSK) announced on November 22, 2021 , has now closed.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 21, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 first quarter ended December 31, 2021 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 12, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome
View HTML
Toggle Summary Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI , which is planned to be the site of an approximately 140,000 square foot
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 17, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 14, 2021 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 30, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 4th Annual Evercore ISI HealthCONx Conference December 2, 2021 , 1:00 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
- Conference Call and Webcast Today, November 22, 2021 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Nov. 22, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2021 . The company is hosting a conference call today,
View HTML